Bar-Joseph Gad, Guilburd Yoav, Tamir Ada, Guilburd Joseph N
Paediatric Critical Care, Meyer Children's Hospital, Rambam Medical Center, Haifa, Israel.
J Neurosurg Pediatr. 2009 Jul;4(1):40-6. doi: 10.3171/2009.1.PEDS08319.
Deepening sedation is often needed in patients with intracranial hypertension. All widely used sedative and anesthetic agents (opioids, benzodiazepines, propofol, and barbiturates) decrease blood pressure and may therefore decrease cerebral perfusion pressure (CPP). Ketamine is a potent, safe, rapid-onset anesthetic agent that does not decrease blood pressure. However, ketamine's use in patients with traumatic brain injury and intracranial hypertension is precluded because it is widely stated that it increases intracranial pressure (ICP). Based on anecdotal clinical experience, the authors hypothesized that ketamine does not increase-but may rather decrease-ICP.
The authors conducted a prospective, controlled, clinical trial of data obtained in a pediatric intensive care unit of a regional trauma center. All patients were sedated and mechanically ventilated prior to inclusion in the study. Children with sustained, elevated ICP (> 18 mm Hg) resistant to first-tier therapies received a single ketamine dose (1-1.5 mg/kg) either to prevent further ICP increase during a potentially distressing intervention (Group 1) or as an additional measure to lower ICP (Group 2). Hemodynamic, ICP, and CPP values were recorded before ketamine administration, and repeated-measures analysis of variance was used to compare these values with those recorded every minute for 10 minutes following ketamine administration.
The results of 82 ketamine administrations in 30 patients were analyzed. Overall, following ketamine administration, ICP decreased by 30% (from 25.8 +/- 8.4 to 18.0 +/- 8.5 mm Hg) (p < 0.001) and CPP increased from 54.4 +/- 11.7 to 58.3 +/- 13.4 mm Hg (p < 0.005). In Group 1, ICP decreased significantly following ketamine administration and increased by > 2 mm Hg during the distressing intervention in only 1 of 17 events. In Group 2, when ketamine was administered to lower persistent intracranial hypertension, ICP decreased by 33% (from 26.0 +/- 9.1 to 17.5 +/- 9.1 mm Hg) (p < 0.0001) following ketamine administration.
In ventilation-treated patients with intracranial hypertension, ketamine effectively decreased ICP and prevented untoward ICP elevations during potentially distressing interventions, without lowering blood pressure and CPP. These results refute the notion that ketamine increases ICP. Ketamine is a safe and effective drug for patients with traumatic brain injury and intracranial hypertension, and it can possibly be used safely in trauma emergency situations.
颅内高压患者常常需要加深镇静。所有广泛使用的镇静和麻醉剂(阿片类药物、苯二氮䓬类药物、丙泊酚和巴比妥类药物)都会降低血压,因此可能会降低脑灌注压(CPP)。氯胺酮是一种强效、安全、起效迅速的麻醉剂,不会降低血压。然而,氯胺酮在创伤性脑损伤和颅内高压患者中的使用受到限制,因为普遍认为它会升高颅内压(ICP)。基于临床经验,作者推测氯胺酮不会升高ICP,反而可能会降低ICP。
作者在一家地区创伤中心的儿科重症监护病房进行了一项前瞻性、对照临床试验,获取相关数据。所有患者在纳入研究前均已接受镇静和机械通气。对一线治疗无效的持续性ICP升高(>18 mmHg)的儿童接受单次氯胺酮剂量(1 - 1.5 mg/kg),要么是为了在可能令人痛苦的干预过程中防止ICP进一步升高(第1组),要么作为降低ICP的额外措施(第2组)。在给予氯胺酮之前记录血流动力学、ICP和CPP值,并使用重复测量方差分析将这些值与给予氯胺酮后10分钟内每分钟记录的值进行比较。
分析了30例患者82次氯胺酮给药的结果。总体而言,给予氯胺酮后,ICP下降了30%(从25.8±